The discovery that the AMPK activator C29 enhances endurance and muscle performance in a time-of-day specific manner, contingent upon intact adipocyte AMPKα2 signaling, carries significant implications for chronopharmacological approaches aimed at optimizing exercise performance and treating metabolic diseases [5]. This evidence concerns the gene PRKAA2 and metabolic disease.